MORI SILVIA

Ruolo: 
Tecnologo
Telefono: 
0264488155
Stanza: 

U38, Piano 05, Stanza 5019
Via Pergolesi, 33 - 20900 MONZA

Pubblicazioni

  • Diral, E., Mori, S., Antolini, L., Abruzzese, E., Le Coutre, P., Martino, B., et al. (2020). Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. BLOOD, 136(19), 2237-2240. Dettaglio
  • Coppo, A., Bellani, G., Winterton, D., Di Pierro, M., Soria, A., Faverio, P., et al. (2020). Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study. THE LANCET RESPIRATORY MEDICINE, 8(8), 765-774 [10.1016/S2213-2600(20)30268-X]. Dettaglio
  • Farina, F., Ceccon, M., Mori, S., Verga, L., Borin, L., Mologni, L., et al. (2017). Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates. Intervento presentato a: Congress of the European-Hematology-Association JUN 22-25, Madrid, Spain. Dettaglio
  • Mori, S., Vagge, E., Le Coutre, P., Abruzzese, E., Martino, B., Pungolino, E., et al. (2015). Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study. AMERICAN JOURNAL OF HEMATOLOGY, 90(10), 910-914 [10.1002/ajh.24120]. Dettaglio
  • Mori, S., Vagge, E., le Coutre, P., Abruzzese, E., Martino, B., Pungolino, E., et al. (2014). The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis. In 56th ASH Annual Meeting and Exposition. Dettaglio